文献速递糖尿病

糖尿病患者使用DPP4抑制剂与肝硬化、终末期肾病及部分癌症发生率的相关性

Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

基于韩国国民健康保险服务数据库(2007-2018年),对747124例成人糖尿病患者进行三项配对比较。与噻唑烷二酮类相比,DPP4抑制剂治疗与肝硬化、终末期肾病、肝癌和胰腺癌的调整风险比更高;除肝硬化外,DPP4抑制剂使用者的上述结局风险也高于非DPP4抑制剂使用者。

要点

  • 与TZD相比,DPP4i与肝硬化(HR 1.267)、ESRD(HR 1.596)、肝癌(HR 1.117)和胰腺癌(HR 1.158)风险升高相关。
  • 除肝硬化外,DPP4i使用者上述结局风险均高于非DPP4i使用者。
  • 长期暴露于DPP4i的患者中,上述调整风险比进一步升高。

核心结论

  • 糖尿病患者使用DPP4抑制剂治疗与肝硬化、癌症、终末期肾病和胰腺癌风险高于噻唑烷二酮类治疗相关,且除肝硬化外,这些结局风险也高于非DPP4抑制剂治疗。

研究设计与样本

  • 基于韩国国民健康保险服务数据库(2007-2018年)的数据,对成人糖尿病患者进行三项二甲双胍联合降糖治疗的配对比较:DPP4抑制剂 vs 所有其他口服降糖药、vs 磺脲类/格列奈类、vs 噻唑烷二酮类。
  • 共纳入747124例患者,其中628217例接受DPP4抑制剂治疗,平均持续33.8±25.0个月。
  • 采用调整Cox模型估计结局的调整风险比(HR)和95%CI。

主要发现

  • 与TZD治疗相比,DPP4i治疗的调整HR(95%CI)为:肝硬化1.267(1.108-1.449)、ESRD 1.596(1.139-2.236)、肝癌1.117(1.011-1.235)、胰腺癌1.158(1.040-1.290)。
  • 除肝硬化外,DPP4i使用与非DPP4i使用相比,上述各结局风险更高。
  • 长期暴露于DPP4i的患者中,与DPP4i使用相关的调整HR进一步升高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There are relatively few data on noncardiovascular (non-CV) long-term clinical outcomes of dipeptidyl peptidase 4 inhibitor (DPP4i) treatment. OBJECTIVE: We aimed to evaluate some non-CV effects of DPP4is in patients with diabetes. METHODS: Based on data from the National Health Insurance Service database in Korea (2007-2018), we conducted 3 pairwise comparisons of metformin-combined antidiabetic therapies in adult patients with diabetes: DPP4is vs (1) all other oral antidiabetic agents, (2) sulfonylureas/glinides, and (3) thiazolidinediones (TZDs). Major outcomes were liver cirrhosis, end-stage renal disease (ESRD), and cancers in the liver, kidney, and pancreas. Adjusted hazard ratios (HRs) and 95% CIs for the outcomes were estimated using an adjusted Cox model. RESULTS: Of the 747 124 patients included, 628 217 had received DPP4i therapy for a mean duration of 33.8 ± 25.0 months. Compared with TZD therapy, DPP4i therapy was associated with higher adjusted HRs [95% CIs] for liver cirrhosis (1.267 [1.108-1.449]), ESRD (1.596 [1.139-2.236]), liver cancer (1.117 [1.011-1.235]), and pancreatic cancer (1.158 [1.040-1.290]). Furthermore, apart from liver cirrhosis, a higher risk of each of these outcomes was associated with DPP4i use than with non-DPP4i use. The higher adjusted HRs associated with DPP4i use further increased when patients with long-term exposure to DPP4is were analyzed. CONCLUSION: DPP4i therapy in patients with diabetes was associated with a higher risk of liver cirrhosis and cancer, ESRD, and pancreatic cancer than TZD therapy and, except for liver cirrhosis, the risk of these outcomes was greater with DPP4i treatment than with non-DPP4i treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Na Y, Kim SW, Park IB, et al. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes. J Clin Endocrinol Metab. 2022. PMID: 36108097. doi:10.1210/clinem/dgac540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。